CD4⁺ T cells activated by AgAb treatment can kill target B lymphoma cells. A 4-hour ⁵¹Cr-release cytotoxicity assay was performed, in which the BL cells (AG876) targeted by AgAb treatment were used as target cells. BL cells were either untreated (medium only) or treated with 1 μg EBNA3C 3H10 peptide (corresponding to 5 μg/mL), 10 ng, or 1 ng antibodies (corresponding to 50 ng/mL and 5 ng/mL; αCD20, αCD19, αCD21, and αCD22) containing the EBNA3C 3H10 epitope, or 10 ng antibody without epitope (corresponding to 50 ng/mL) for 24 hours. BL cells were then incubated with CD4⁺ T cells specific to the EBNA3C 3H10 epitope for 4 hours at varying E:T ratios. Cell lysis was determined by ⁵¹Cr release. All assays were performed in triplicate wells and means and standard deviations are shown.